MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6505-1111-1119$20.00
Mol Pharmacol 65:1111-1119, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, M. S.
Right arrow Articles by Dostmann, W. R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, M. S.
Right arrow Articles by Dostmann, W. R. G.

Inhibition of cGMP-Dependent Protein Kinase by the Cell-Permeable Peptide DT-2 Reveals a Novel Mechanism of Vasoregulation

Mark S. Taylor1, Chris Okwuchukwuasanya, Christian K. Nickl, Werner Tegge, Joseph E. Brayden , and Wolfgang R. G. Dostmann

Department of Pharmacology, University of Vermont, College of Medicine, Burlington, Vermont (M.S.T., C.O., C.K.N., J.E.B., W.R.G.D.); and German Research Centre for Biotechnology, Chemical Biology, Braunschweig, Germany (W.J.T.)

Cyclic GMP-dependent protein kinase (PKG) serves as an important physiological regulator of vascular reactivity and tone. However, available inhibitors of PKG have exhibited variable effects in intact tissue, hindering the elucidation of the functional role of PKG in blood vessels. In this study, we have determined the effects of our previously engineered potent and selective PKG I{alpha} inhibitor DT-2 on basal and cGMP-stimulated purified recombinant PKG, and compared DT-2 with commonly used PKG inhibitors (8R,9S,11S)-(–)-9-methoxy-carbamyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-trizadibenzo-(a,g)-cycloocta-(c,d,e)-trinden-1-one (KT-5823), Rp-8-(4-chlorophenylthio)-guanosine-3',5'-cyclic monophosphorothioate (Rp-8-pCPT-cGMPS), and ({beta}-phenyl-1,N2-etheno-8-bromoguanosine-3',5'-cyclic monophosphorothioate, Rp-isomer (Rp-8-Br-PET-cGMPS). As expected, all inhibitors reduced cGMP-stimulated PKG activity. However, only DT-2 decreased cGMP-independent or basal PKG activity, whereas KT5823 showed no effect and the Rp-compounds actually had partial agonist activity. To evaluate the potential functional impact of this unique inhibition by DT-2 under physiologically relevant conditions, we analyzed the inhibitors in isolated pressurized cerebral arteries. KT-5823 and Rp-8-pCPT-cGMPS demonstrated marginal reversal of vasodilation induced by 8-Br-cGMP. By comparison, DT-2 completely reversed 8-Br-cGMP induced dilations with comparable potency to Rp-8-Br-PET-cGMPS. In fact, DT-2 constricted arteries beyond their starting (pre-8-Br-cGMP) diameters and caused constriction even in the absence of exogenous 8-Br-cGMP, an effect that was not observed with any other inhibitor. The direct constricting effect of DT-2 was essentially abolished in cultured arteries, where PKG expression was reduced by approximately 90%. These findings indicate that DT-2 not only effectively inhibits cGMP-stimulated PKG activity but also reduces basal PKG activity both in vitro and in vivo. Moreover, these distinctive inhibitory properties of DT-2 suggest an important role for constitutive PKG activity in the continuous regulation of cerebral artery tone.


Received November 12, 2003; accepted February 6, 2004.

Address correspondence to: Dr. Wolfgang Dostmann, University of Vermont, Department of Pharmacology, Health Science Research Facility 330, 149 Beaumont Avenue, Burlington, VT 05405-0075. E-mail: wolfgang.dostmann{at}uvm.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. W. H. Pinkse, D. T. S. Rijkers, W. R. Dostmann, and A. J. R. Heck
Mode of Action of cGMP-dependent Protein Kinase-specific Inhibitors Probed by Photoaffinity Cross-linking Mass Spectrometry
J. Biol. Chem., June 12, 2009; 284(24): 16354 - 16368.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Valtcheva, P. Nestorov, A. Beck, M. Russwurm, M. Hillenbrand, P. Weinmeister, and R. Feil
The Commonly Used cGMP-dependent Protein Kinase Type I (cGKI) Inhibitor Rp-8-Br-PET-cGMPS Can Activate cGKI in Vitro and in Intact Cells
J. Biol. Chem., January 2, 2009; 284(1): 556 - 562.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
P. F. Bove, U. V. Wesley, A.-K. Greul, M. Hristova, W. R. Dostmann, and A. van der Vliet
Nitric Oxide Promotes Airway Epithelial Wound Repair through Enhanced Activation of MMP-9
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 138 - 146.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. N. Christensen and M. E. Mendelsohn
Cyclic GMP-dependent Protein Kinase I{alpha} Inhibits Thrombin Receptor-mediated Calcium Mobilization in Vascular Smooth Muscle Cells
J. Biol. Chem., March 31, 2006; 281(13): 8409 - 8416.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Krieg, S. Philipp, L. Cui, W. R. Dostmann, J. M. Downey, and M. V. Cohen
Peptide blockers of PKG inhibit ROS generation by acetylcholine and bradykinin in cardiomyocytes but fail to block protection in the whole heart
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1976 - H1981.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics